Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBIO) Stock Competitors & Peer Comparison
See (PBIO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PBIO | $0.00 | -66.67% | 4.1K | N/A | -$0.83 | N/A |
| SMMNY | $28.16 | +0.97% | 127.2B | 25.78 | $1.09 | +1.04% |
| SEMHF | $56.60 | +0.43% | 63.5B | 25.84 | $2.19 | +1.75% |
| RYLPF | $28.00 | +8.78% | 26.5B | 90.32 | $0.31 | +3.39% |
| SONVY | $54.96 | -4.55% | 16.4B | 24.20 | $2.27 | +1.14% |
| SONVF | $271.87 | -7.43% | 16.2B | 23.70 | $11.47 | +1.92% |
| CHEOY | $101.52 | -2.43% | 13.3B | 54.83 | $1.85 | +1.32% |
| CHEOF | $202.69 | +0.36% | 13.2B | 52.51 | $3.86 | +1.37% |
| SNNUF | $14.94 | +0.00% | 13.1B | 31.79 | $0.47 | +2.51% |
| WILYY | $20.19 | +0.00% | 8.6B | 19.23 | $1.05 | N/A |
Stock Comparison
PBIO vs SMMNY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, SMMNY has a market cap of 127.2B. Regarding current trading prices, PBIO is priced at $0.00, while SMMNY trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas SMMNY's P/E ratio is 25.78. In terms of profitability, PBIO's ROE is +0.70%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, PBIO is less volatile compared to SMMNY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check SMMNY's competition here
PBIO vs SEMHF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, SEMHF has a market cap of 63.5B. Regarding current trading prices, PBIO is priced at $0.00, while SEMHF trades at $56.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas SEMHF's P/E ratio is 25.84. In terms of profitability, PBIO's ROE is +0.70%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, PBIO and SEMHF have similar daily volatility (0.00).Check SEMHF's competition here
PBIO vs RYLPF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, RYLPF has a market cap of 26.5B. Regarding current trading prices, PBIO is priced at $0.00, while RYLPF trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas RYLPF's P/E ratio is 90.32. In terms of profitability, PBIO's ROE is +0.70%, compared to RYLPF's ROE of +0.03%. Regarding short-term risk, PBIO is less volatile compared to RYLPF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check RYLPF's competition here
PBIO vs SONVY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, SONVY has a market cap of 16.4B. Regarding current trading prices, PBIO is priced at $0.00, while SONVY trades at $54.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas SONVY's P/E ratio is 24.20. In terms of profitability, PBIO's ROE is +0.70%, compared to SONVY's ROE of +0.21%. Regarding short-term risk, PBIO is less volatile compared to SONVY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check SONVY's competition here
PBIO vs SONVF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, SONVF has a market cap of 16.2B. Regarding current trading prices, PBIO is priced at $0.00, while SONVF trades at $271.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas SONVF's P/E ratio is 23.70. In terms of profitability, PBIO's ROE is +0.70%, compared to SONVF's ROE of +0.22%. Regarding short-term risk, PBIO and SONVF have similar daily volatility (0.00).Check SONVF's competition here
PBIO vs CHEOY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CHEOY has a market cap of 13.3B. Regarding current trading prices, PBIO is priced at $0.00, while CHEOY trades at $101.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CHEOY's P/E ratio is 54.83. In terms of profitability, PBIO's ROE is +0.70%, compared to CHEOY's ROE of +0.20%. Regarding short-term risk, PBIO is less volatile compared to CHEOY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check CHEOY's competition here
PBIO vs CHEOF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CHEOF has a market cap of 13.2B. Regarding current trading prices, PBIO is priced at $0.00, while CHEOF trades at $202.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CHEOF's P/E ratio is 52.51. In terms of profitability, PBIO's ROE is +0.70%, compared to CHEOF's ROE of +0.20%. Regarding short-term risk, PBIO and CHEOF have similar daily volatility (0.00).Check CHEOF's competition here
PBIO vs SNNUF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, SNNUF has a market cap of 13.1B. Regarding current trading prices, PBIO is priced at $0.00, while SNNUF trades at $14.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas SNNUF's P/E ratio is 31.79. In terms of profitability, PBIO's ROE is +0.70%, compared to SNNUF's ROE of +0.08%. Regarding short-term risk, PBIO is less volatile compared to SNNUF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check SNNUF's competition here
PBIO vs WILYY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, WILYY has a market cap of 8.6B. Regarding current trading prices, PBIO is priced at $0.00, while WILYY trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas WILYY's P/E ratio is 19.23. In terms of profitability, PBIO's ROE is +0.70%, compared to WILYY's ROE of +0.25%. Regarding short-term risk, PBIO is less volatile compared to WILYY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check WILYY's competition here
PBIO vs WILLF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, WILLF has a market cap of 7.9B. Regarding current trading prices, PBIO is priced at $0.00, while WILLF trades at $38.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas WILLF's P/E ratio is 18.42. In terms of profitability, PBIO's ROE is +0.70%, compared to WILLF's ROE of +0.25%. Regarding short-term risk, PBIO is less volatile compared to WILLF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check WILLF's competition here
PBIO vs GNGBF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, GNGBF has a market cap of 5.7B. Regarding current trading prices, PBIO is priced at $0.00, while GNGBF trades at $21.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas GNGBF's P/E ratio is 36.84. In terms of profitability, PBIO's ROE is +0.70%, compared to GNGBF's ROE of +0.05%. Regarding short-term risk, PBIO is less volatile compared to GNGBF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check GNGBF's competition here
PBIO vs GNGBY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, GNGBY has a market cap of 5.5B. Regarding current trading prices, PBIO is priced at $0.00, while GNGBY trades at $19.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas GNGBY's P/E ratio is 35.05. In terms of profitability, PBIO's ROE is +0.70%, compared to GNGBY's ROE of +0.05%. Regarding short-term risk, PBIO is less volatile compared to GNGBY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check GNGBY's competition here
PBIO vs AMBBY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, AMBBY has a market cap of 4.1B. Regarding current trading prices, PBIO is priced at $0.00, while AMBBY trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas AMBBY's P/E ratio is 69.52. In terms of profitability, PBIO's ROE is +0.70%, compared to AMBBY's ROE of +0.06%. Regarding short-term risk, PBIO and AMBBY have similar daily volatility (0.00).Check AMBBY's competition here
PBIO vs AMBFF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, AMBFF has a market cap of 4B. Regarding current trading prices, PBIO is priced at $0.00, while AMBFF trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas AMBFF's P/E ratio is 69.09. In terms of profitability, PBIO's ROE is +0.70%, compared to AMBFF's ROE of +0.06%. Regarding short-term risk, PBIO is less volatile compared to AMBFF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check AMBFF's competition here
PBIO vs NHNKY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, NHNKY has a market cap of 3.7B. Regarding current trading prices, PBIO is priced at $0.00, while NHNKY trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas NHNKY's P/E ratio is 19.72. In terms of profitability, PBIO's ROE is +0.70%, compared to NHNKY's ROE of +0.08%. Regarding short-term risk, PBIO is less volatile compared to NHNKY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check NHNKY's competition here
PBIO vs MCRPF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, MCRPF has a market cap of 3B. Regarding current trading prices, PBIO is priced at $0.00, while MCRPF trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas MCRPF's P/E ratio is -13.42. In terms of profitability, PBIO's ROE is +0.70%, compared to MCRPF's ROE of -0.33%. Regarding short-term risk, PBIO and MCRPF have similar daily volatility (0.00).Check MCRPF's competition here
PBIO vs NHNKF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, NHNKF has a market cap of 2.5B. Regarding current trading prices, PBIO is priced at $0.00, while NHNKF trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas NHNKF's P/E ratio is 41.86. In terms of profitability, PBIO's ROE is +0.70%, compared to NHNKF's ROE of +0.08%. Regarding short-term risk, PBIO and NHNKF have similar daily volatility (0.00).Check NHNKF's competition here
PBIO vs GNNDY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, GNNDY has a market cap of 2.3B. Regarding current trading prices, PBIO is priced at $0.00, while GNNDY trades at $48.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas GNNDY's P/E ratio is 18.54. In terms of profitability, PBIO's ROE is +0.70%, compared to GNNDY's ROE of +0.08%. Regarding short-term risk, PBIO is less volatile compared to GNNDY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check GNNDY's competition here
PBIO vs GGNDF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, GGNDF has a market cap of 2.1B. Regarding current trading prices, PBIO is priced at $0.00, while GGNDF trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas GGNDF's P/E ratio is 16.53. In terms of profitability, PBIO's ROE is +0.70%, compared to GGNDF's ROE of +0.08%. Regarding short-term risk, PBIO is less volatile compared to GGNDF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check GGNDF's competition here
PBIO vs STSEY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, STSEY has a market cap of 2B. Regarding current trading prices, PBIO is priced at $0.00, while STSEY trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas STSEY's P/E ratio is 39.41. In terms of profitability, PBIO's ROE is +0.70%, compared to STSEY's ROE of +0.07%. Regarding short-term risk, PBIO and STSEY have similar daily volatility (0.00).Check STSEY's competition here
PBIO vs VTRLY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, VTRLY has a market cap of 2B. Regarding current trading prices, PBIO is priced at $0.00, while VTRLY trades at $14.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas VTRLY's P/E ratio is 42.80. In terms of profitability, PBIO's ROE is +0.70%, compared to VTRLY's ROE of +0.04%. Regarding short-term risk, PBIO is less volatile compared to VTRLY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check VTRLY's competition here
PBIO vs OSSFF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, OSSFF has a market cap of 1.8B. Regarding current trading prices, PBIO is priced at $0.00, while OSSFF trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas OSSFF's P/E ratio is 24.41. In terms of profitability, PBIO's ROE is +0.70%, compared to OSSFF's ROE of +0.09%. Regarding short-term risk, PBIO is less volatile compared to OSSFF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check OSSFF's competition here
PBIO vs DWRKF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, PBIO is priced at $0.00, while DWRKF trades at $543.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, PBIO's ROE is +0.70%, compared to DWRKF's ROE of N/A. Regarding short-term risk, PBIO and DWRKF have similar daily volatility (0.00).Check DWRKF's competition here
PBIO vs OSSUY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, OSSUY has a market cap of 1.7B. Regarding current trading prices, PBIO is priced at $0.00, while OSSUY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas OSSUY's P/E ratio is 23.53. In terms of profitability, PBIO's ROE is +0.70%, compared to OSSUY's ROE of +0.09%. Regarding short-term risk, PBIO and OSSUY have similar daily volatility (0.00).Check OSSUY's competition here
PBIO vs MEDGF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, PBIO is priced at $0.00, while MEDGF trades at $83.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, PBIO's ROE is +0.70%, compared to MEDGF's ROE of +0.16%. Regarding short-term risk, PBIO and MEDGF have similar daily volatility (0.00).Check MEDGF's competition here
PBIO vs DRWKF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, DRWKF has a market cap of 1.4B. Regarding current trading prices, PBIO is priced at $0.00, while DRWKF trades at $67.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas DRWKF's P/E ratio is 9.40. In terms of profitability, PBIO's ROE is +0.70%, compared to DRWKF's ROE of +0.09%. Regarding short-term risk, PBIO is less volatile compared to DRWKF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check DRWKF's competition here
PBIO vs DGWPF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, DGWPF has a market cap of 1.2B. Regarding current trading prices, PBIO is priced at $0.00, while DGWPF trades at $57.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas DGWPF's P/E ratio is 7.93. In terms of profitability, PBIO's ROE is +0.70%, compared to DGWPF's ROE of +0.09%. Regarding short-term risk, PBIO is less volatile compared to DGWPF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check DGWPF's competition here
PBIO vs ELEAF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ELEAF has a market cap of 1.1B. Regarding current trading prices, PBIO is priced at $0.00, while ELEAF trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ELEAF's P/E ratio is 15.51. In terms of profitability, PBIO's ROE is +0.70%, compared to ELEAF's ROE of +0.15%. Regarding short-term risk, PBIO is less volatile compared to ELEAF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check ELEAF's competition here
PBIO vs LFTSF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, LFTSF has a market cap of 1B. Regarding current trading prices, PBIO is priced at $0.00, while LFTSF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas LFTSF's P/E ratio is 23.35. In terms of profitability, PBIO's ROE is +0.70%, compared to LFTSF's ROE of +0.07%. Regarding short-term risk, PBIO and LFTSF have similar daily volatility (0.00).Check LFTSF's competition here
PBIO vs MDRSF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, MDRSF has a market cap of 828.1M. Regarding current trading prices, PBIO is priced at $0.00, while MDRSF trades at $66.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas MDRSF's P/E ratio is 196.12. In terms of profitability, PBIO's ROE is +0.70%, compared to MDRSF's ROE of +0.01%. Regarding short-term risk, PBIO is less volatile compared to MDRSF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check MDRSF's competition here
PBIO vs XVIPF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, XVIPF has a market cap of 724.5M. Regarding current trading prices, PBIO is priced at $0.00, while XVIPF trades at $23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas XVIPF's P/E ratio is 62.16. In terms of profitability, PBIO's ROE is +0.70%, compared to XVIPF's ROE of +0.07%. Regarding short-term risk, PBIO and XVIPF have similar daily volatility (0.00).Check XVIPF's competition here
PBIO vs CALZF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CALZF has a market cap of 584.5M. Regarding current trading prices, PBIO is priced at $0.00, while CALZF trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CALZF's P/E ratio is 84.60. In terms of profitability, PBIO's ROE is +0.70%, compared to CALZF's ROE of +0.07%. Regarding short-term risk, PBIO is less volatile compared to CALZF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check CALZF's competition here
PBIO vs AVMR Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, PBIO is priced at $0.00, while AVMR trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas AVMR's P/E ratio is -18.34. In terms of profitability, PBIO's ROE is +0.70%, compared to AVMR's ROE of -1.38%. Regarding short-term risk, PBIO and AVMR have similar daily volatility (0.00).Check AVMR's competition here
PBIO vs CLVSF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CLVSF has a market cap of 459.8M. Regarding current trading prices, PBIO is priced at $0.00, while CLVSF trades at $19.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CLVSF's P/E ratio is 31.61. In terms of profitability, PBIO's ROE is +0.70%, compared to CLVSF's ROE of +0.19%. Regarding short-term risk, PBIO is less volatile compared to CLVSF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check CLVSF's competition here
PBIO vs IOBCF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, IOBCF has a market cap of 421.6M. Regarding current trading prices, PBIO is priced at $0.00, while IOBCF trades at $14.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas IOBCF's P/E ratio is 38.89. In terms of profitability, PBIO's ROE is +0.70%, compared to IOBCF's ROE of +0.09%. Regarding short-term risk, PBIO is less volatile compared to IOBCF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check IOBCF's competition here
PBIO vs CSSPF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CSSPF has a market cap of 384M. Regarding current trading prices, PBIO is priced at $0.00, while CSSPF trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CSSPF's P/E ratio is 92.00. In terms of profitability, PBIO's ROE is +0.70%, compared to CSSPF's ROE of +0.16%. Regarding short-term risk, PBIO is less volatile compared to CSSPF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check CSSPF's competition here
PBIO vs HYBT Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, PBIO is priced at $0.00, while HYBT trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas HYBT's P/E ratio is N/A. In terms of profitability, PBIO's ROE is +0.70%, compared to HYBT's ROE of -0.00%. Regarding short-term risk, PBIO and HYBT have similar daily volatility (0.00).Check HYBT's competition here
PBIO vs EAPIF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, EAPIF has a market cap of 347.6M. Regarding current trading prices, PBIO is priced at $0.00, while EAPIF trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas EAPIF's P/E ratio is -2.25. In terms of profitability, PBIO's ROE is +0.70%, compared to EAPIF's ROE of -0.31%. Regarding short-term risk, PBIO is less volatile compared to EAPIF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check EAPIF's competition here
PBIO vs CYBQY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CYBQY has a market cap of 315.1M. Regarding current trading prices, PBIO is priced at $0.00, while CYBQY trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CYBQY's P/E ratio is -74.00. In terms of profitability, PBIO's ROE is +0.70%, compared to CYBQY's ROE of -0.01%. Regarding short-term risk, PBIO and CYBQY have similar daily volatility (0.00).Check CYBQY's competition here
PBIO vs CLLKF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CLLKF has a market cap of 272.9M. Regarding current trading prices, PBIO is priced at $0.00, while CLLKF trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CLLKF's P/E ratio is -8.59. In terms of profitability, PBIO's ROE is +0.70%, compared to CLLKF's ROE of -0.12%. Regarding short-term risk, PBIO and CLLKF have similar daily volatility (0.00).Check CLLKF's competition here
PBIO vs BRSYF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, BRSYF has a market cap of 256.3M. Regarding current trading prices, PBIO is priced at $0.00, while BRSYF trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas BRSYF's P/E ratio is 61.64. In terms of profitability, PBIO's ROE is +0.70%, compared to BRSYF's ROE of +0.07%. Regarding short-term risk, PBIO is less volatile compared to BRSYF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check BRSYF's competition here
PBIO vs HTLZF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, PBIO is priced at $0.00, while HTLZF trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, PBIO's ROE is +0.70%, compared to HTLZF's ROE of -0.03%. Regarding short-term risk, PBIO and HTLZF have similar daily volatility (0.00).Check HTLZF's competition here
PBIO vs BCCOY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, BCCOY has a market cap of 221M. Regarding current trading prices, PBIO is priced at $0.00, while BCCOY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas BCCOY's P/E ratio is -7.27. In terms of profitability, PBIO's ROE is +0.70%, compared to BCCOY's ROE of -0.12%. Regarding short-term risk, PBIO is less volatile compared to BCCOY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check BCCOY's competition here
PBIO vs IMPZY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, IMPZY has a market cap of 199.9M. Regarding current trading prices, PBIO is priced at $0.00, while IMPZY trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, PBIO's ROE is +0.70%, compared to IMPZY's ROE of -2.86%. Regarding short-term risk, PBIO and IMPZY have similar daily volatility (0.00).Check IMPZY's competition here
PBIO vs PXMBF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, PXMBF has a market cap of 181.6M. Regarding current trading prices, PBIO is priced at $0.00, while PXMBF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas PXMBF's P/E ratio is 29.17. In terms of profitability, PBIO's ROE is +0.70%, compared to PXMBF's ROE of +0.12%. Regarding short-term risk, PBIO and PXMBF have similar daily volatility (0.00).Check PXMBF's competition here
PBIO vs DTXMF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, DTXMF has a market cap of 180.6M. Regarding current trading prices, PBIO is priced at $0.00, while DTXMF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas DTXMF's P/E ratio is -9.52. In terms of profitability, PBIO's ROE is +0.70%, compared to DTXMF's ROE of -0.41%. Regarding short-term risk, PBIO is less volatile compared to DTXMF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check DTXMF's competition here
PBIO vs DMTRF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, DMTRF has a market cap of 165.6M. Regarding current trading prices, PBIO is priced at $0.00, while DMTRF trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas DMTRF's P/E ratio is -9.86. In terms of profitability, PBIO's ROE is +0.70%, compared to DMTRF's ROE of -0.24%. Regarding short-term risk, PBIO is less volatile compared to DMTRF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check DMTRF's competition here
PBIO vs CYBQF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CYBQF has a market cap of 160.1M. Regarding current trading prices, PBIO is priced at $0.00, while CYBQF trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CYBQF's P/E ratio is -60.00. In terms of profitability, PBIO's ROE is +0.70%, compared to CYBQF's ROE of -0.01%. Regarding short-term risk, PBIO is less volatile compared to CYBQF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check CYBQF's competition here
PBIO vs EKDHF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, EKDHF has a market cap of 157.2M. Regarding current trading prices, PBIO is priced at $0.00, while EKDHF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas EKDHF's P/E ratio is 17.50. In terms of profitability, PBIO's ROE is +0.70%, compared to EKDHF's ROE of +0.09%. Regarding short-term risk, PBIO and EKDHF have similar daily volatility (0.00).Check EKDHF's competition here
PBIO vs AVHHL Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, AVHHL has a market cap of 153.3M. Regarding current trading prices, PBIO is priced at $0.00, while AVHHL trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas AVHHL's P/E ratio is -3.07. In terms of profitability, PBIO's ROE is +0.70%, compared to AVHHL's ROE of -3.38%. Regarding short-term risk, PBIO and AVHHL have similar daily volatility (0.00).Check AVHHL's competition here
PBIO vs AMEUF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, PBIO is priced at $0.00, while AMEUF trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, PBIO's ROE is +0.70%, compared to AMEUF's ROE of -5.13%. Regarding short-term risk, PBIO is less volatile compared to AMEUF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check AMEUF's competition here
PBIO vs SNZZF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, SNZZF has a market cap of 111.9M. Regarding current trading prices, PBIO is priced at $0.00, while SNZZF trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas SNZZF's P/E ratio is -7.12. In terms of profitability, PBIO's ROE is +0.70%, compared to SNZZF's ROE of -0.40%. Regarding short-term risk, PBIO and SNZZF have similar daily volatility (0.00).Check SNZZF's competition here
PBIO vs VMTHF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, VMTHF has a market cap of 110M. Regarding current trading prices, PBIO is priced at $0.00, while VMTHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas VMTHF's P/E ratio is -1.09. In terms of profitability, PBIO's ROE is +0.70%, compared to VMTHF's ROE of -0.23%. Regarding short-term risk, PBIO is less volatile compared to VMTHF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check VMTHF's competition here
PBIO vs JMDMF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, JMDMF has a market cap of 104.4M. Regarding current trading prices, PBIO is priced at $0.00, while JMDMF trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas JMDMF's P/E ratio is -27.83. In terms of profitability, PBIO's ROE is +0.70%, compared to JMDMF's ROE of N/A. Regarding short-term risk, PBIO is less volatile compared to JMDMF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check JMDMF's competition here
PBIO vs IPDQF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, IPDQF has a market cap of 104.2M. Regarding current trading prices, PBIO is priced at $0.00, while IPDQF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas IPDQF's P/E ratio is -5.14. In terms of profitability, PBIO's ROE is +0.70%, compared to IPDQF's ROE of -0.43%. Regarding short-term risk, PBIO is less volatile compared to IPDQF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check IPDQF's competition here
PBIO vs RSHUF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, PBIO is priced at $0.00, while RSHUF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, PBIO's ROE is +0.70%, compared to RSHUF's ROE of -2.32%. Regarding short-term risk, PBIO is less volatile compared to RSHUF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check RSHUF's competition here
PBIO vs SOMNF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, SOMNF has a market cap of 90.8M. Regarding current trading prices, PBIO is priced at $0.00, while SOMNF trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas SOMNF's P/E ratio is -14.00. In terms of profitability, PBIO's ROE is +0.70%, compared to SOMNF's ROE of -0.38%. Regarding short-term risk, PBIO is less volatile compared to SOMNF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check SOMNF's competition here
PBIO vs CKMTF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, PBIO is priced at $0.00, while CKMTF trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, PBIO's ROE is +0.70%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, PBIO and CKMTF have similar daily volatility (0.00).Check CKMTF's competition here
PBIO vs FDMDF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, FDMDF has a market cap of 75.7M. Regarding current trading prices, PBIO is priced at $0.00, while FDMDF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas FDMDF's P/E ratio is -2.03. In terms of profitability, PBIO's ROE is +0.70%, compared to FDMDF's ROE of -0.44%. Regarding short-term risk, PBIO is less volatile compared to FDMDF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check FDMDF's competition here
PBIO vs RDGL Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, RDGL has a market cap of 57.6M. Regarding current trading prices, PBIO is priced at $0.00, while RDGL trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas RDGL's P/E ratio is -12.70. In terms of profitability, PBIO's ROE is +0.70%, compared to RDGL's ROE of -1.57%. Regarding short-term risk, PBIO is less volatile compared to RDGL. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check RDGL's competition here
PBIO vs BLOZF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, BLOZF has a market cap of 50.4M. Regarding current trading prices, PBIO is priced at $0.00, while BLOZF trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas BLOZF's P/E ratio is -21.88. In terms of profitability, PBIO's ROE is +0.70%, compared to BLOZF's ROE of -0.89%. Regarding short-term risk, PBIO is less volatile compared to BLOZF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check BLOZF's competition here
PBIO vs BRNHF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, BRNHF has a market cap of 42.2M. Regarding current trading prices, PBIO is priced at $0.00, while BRNHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas BRNHF's P/E ratio is -1.33. In terms of profitability, PBIO's ROE is +0.70%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, PBIO and BRNHF have similar daily volatility (0.00).Check BRNHF's competition here
PBIO vs NVYTF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, NVYTF has a market cap of 38.9M. Regarding current trading prices, PBIO is priced at $0.00, while NVYTF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas NVYTF's P/E ratio is -0.74. In terms of profitability, PBIO's ROE is +0.70%, compared to NVYTF's ROE of +0.00%. Regarding short-term risk, PBIO is less volatile compared to NVYTF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check NVYTF's competition here
PBIO vs TLTFF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, TLTFF has a market cap of 37.3M. Regarding current trading prices, PBIO is priced at $0.00, while TLTFF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas TLTFF's P/E ratio is -14.85. In terms of profitability, PBIO's ROE is +0.70%, compared to TLTFF's ROE of -2.57%. Regarding short-term risk, PBIO is less volatile compared to TLTFF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check TLTFF's competition here
PBIO vs ELXMF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ELXMF has a market cap of 28.4M. Regarding current trading prices, PBIO is priced at $0.00, while ELXMF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ELXMF's P/E ratio is -2.00. In terms of profitability, PBIO's ROE is +0.70%, compared to ELXMF's ROE of -0.46%. Regarding short-term risk, PBIO and ELXMF have similar daily volatility (0.00).Check ELXMF's competition here
PBIO vs POSC Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, POSC has a market cap of 27.6M. Regarding current trading prices, PBIO is priced at $0.00, while POSC trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas POSC's P/E ratio is 0.37. In terms of profitability, PBIO's ROE is +0.70%, compared to POSC's ROE of +9.25%. Regarding short-term risk, PBIO is less volatile compared to POSC. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check POSC's competition here
PBIO vs MKEAF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, PBIO is priced at $0.00, while MKEAF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, PBIO's ROE is +0.70%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, PBIO and MKEAF have similar daily volatility (0.00).Check MKEAF's competition here
PBIO vs EMITF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, EMITF has a market cap of 24.6M. Regarding current trading prices, PBIO is priced at $0.00, while EMITF trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas EMITF's P/E ratio is -13.21. In terms of profitability, PBIO's ROE is +0.70%, compared to EMITF's ROE of +0.05%. Regarding short-term risk, PBIO is less volatile compared to EMITF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check EMITF's competition here
PBIO vs KBBTF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, PBIO is priced at $0.00, while KBBTF trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, PBIO's ROE is +0.70%, compared to KBBTF's ROE of N/A. Regarding short-term risk, PBIO and KBBTF have similar daily volatility (0.00).Check KBBTF's competition here
PBIO vs GTHP Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, GTHP has a market cap of 19.7M. Regarding current trading prices, PBIO is priced at $0.00, while GTHP trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas GTHP's P/E ratio is -5.00. In terms of profitability, PBIO's ROE is +0.70%, compared to GTHP's ROE of +0.78%. Regarding short-term risk, PBIO and GTHP have similar daily volatility (0.00).Check GTHP's competition here
PBIO vs ASAPF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ASAPF has a market cap of 18.6M. Regarding current trading prices, PBIO is priced at $0.00, while ASAPF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ASAPF's P/E ratio is -23.79. In terms of profitability, PBIO's ROE is +0.70%, compared to ASAPF's ROE of -0.23%. Regarding short-term risk, PBIO is less volatile compared to ASAPF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check ASAPF's competition here
PBIO vs DIZTF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, PBIO is priced at $0.00, while DIZTF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, PBIO's ROE is +0.70%, compared to DIZTF's ROE of -2.22%. Regarding short-term risk, PBIO is less volatile compared to DIZTF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check DIZTF's competition here
PBIO vs VPTDF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, VPTDF has a market cap of 17.9M. Regarding current trading prices, PBIO is priced at $0.00, while VPTDF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas VPTDF's P/E ratio is -5.35. In terms of profitability, PBIO's ROE is +0.70%, compared to VPTDF's ROE of +1.70%. Regarding short-term risk, PBIO is less volatile compared to VPTDF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check VPTDF's competition here
PBIO vs PYNKF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, PYNKF has a market cap of 17.8M. Regarding current trading prices, PBIO is priced at $0.00, while PYNKF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas PYNKF's P/E ratio is -0.86. In terms of profitability, PBIO's ROE is +0.70%, compared to PYNKF's ROE of -1.58%. Regarding short-term risk, PBIO is less volatile compared to PYNKF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check PYNKF's competition here
PBIO vs MDXHF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, MDXHF has a market cap of 14.2M. Regarding current trading prices, PBIO is priced at $0.00, while MDXHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas MDXHF's P/E ratio is -0.08. In terms of profitability, PBIO's ROE is +0.70%, compared to MDXHF's ROE of +0.49%. Regarding short-term risk, PBIO and MDXHF have similar daily volatility (0.00).Check MDXHF's competition here
PBIO vs TMDIF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, PBIO is priced at $0.00, while TMDIF trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, PBIO's ROE is +0.70%, compared to TMDIF's ROE of -1.38%. Regarding short-term risk, PBIO is less volatile compared to TMDIF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check TMDIF's competition here
PBIO vs PLLWF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, PLLWF has a market cap of 13.3M. Regarding current trading prices, PBIO is priced at $0.00, while PLLWF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas PLLWF's P/E ratio is -1.10. In terms of profitability, PBIO's ROE is +0.70%, compared to PLLWF's ROE of -0.61%. Regarding short-term risk, PBIO is less volatile compared to PLLWF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check PLLWF's competition here
PBIO vs IMEXF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, IMEXF has a market cap of 11.8M. Regarding current trading prices, PBIO is priced at $0.00, while IMEXF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas IMEXF's P/E ratio is N/A. In terms of profitability, PBIO's ROE is +0.70%, compared to IMEXF's ROE of +0.20%. Regarding short-term risk, PBIO is less volatile compared to IMEXF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check IMEXF's competition here
PBIO vs ATBPF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, PBIO is priced at $0.00, while ATBPF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, PBIO's ROE is +0.70%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, PBIO is less volatile compared to ATBPF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check ATBPF's competition here
PBIO vs LXXGF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, PBIO is priced at $0.00, while LXXGF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, PBIO's ROE is +0.70%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, PBIO and LXXGF have similar daily volatility (0.00).Check LXXGF's competition here
PBIO vs RMSL Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, RMSL has a market cap of 10.4M. Regarding current trading prices, PBIO is priced at $0.00, while RMSL trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas RMSL's P/E ratio is 0.68. In terms of profitability, PBIO's ROE is +0.70%, compared to RMSL's ROE of -2.03%. Regarding short-term risk, PBIO is less volatile compared to RMSL. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check RMSL's competition here
PBIO vs NGMDF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, NGMDF has a market cap of 8.5M. Regarding current trading prices, PBIO is priced at $0.00, while NGMDF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas NGMDF's P/E ratio is -3.74. In terms of profitability, PBIO's ROE is +0.70%, compared to NGMDF's ROE of +0.36%. Regarding short-term risk, PBIO and NGMDF have similar daily volatility (0.00).Check NGMDF's competition here
PBIO vs FZMD Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, FZMD has a market cap of 7.4M. Regarding current trading prices, PBIO is priced at $0.00, while FZMD trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas FZMD's P/E ratio is 2.00. In terms of profitability, PBIO's ROE is +0.70%, compared to FZMD's ROE of +0.13%. Regarding short-term risk, PBIO is less volatile compared to FZMD. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check FZMD's competition here
PBIO vs ALRTF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ALRTF has a market cap of 5.7M. Regarding current trading prices, PBIO is priced at $0.00, while ALRTF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ALRTF's P/E ratio is -0.30. In terms of profitability, PBIO's ROE is +0.70%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, PBIO and ALRTF have similar daily volatility (0.00).Check ALRTF's competition here
PBIO vs QLIS Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, PBIO is priced at $0.00, while QLIS trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas QLIS's P/E ratio is 2.22. In terms of profitability, PBIO's ROE is +0.70%, compared to QLIS's ROE of -1.41%. Regarding short-term risk, PBIO and QLIS have similar daily volatility (0.00).Check QLIS's competition here
PBIO vs RHNMF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, PBIO is priced at $0.00, while RHNMF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, PBIO's ROE is +0.70%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, PBIO is less volatile compared to RHNMF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check RHNMF's competition here
PBIO vs VYCO Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, VYCO has a market cap of 4.3M. Regarding current trading prices, PBIO is priced at $0.00, while VYCO trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas VYCO's P/E ratio is -13.00. In terms of profitability, PBIO's ROE is +0.70%, compared to VYCO's ROE of +0.03%. Regarding short-term risk, PBIO and VYCO have similar daily volatility (0.00).Check VYCO's competition here
PBIO vs LBLTF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, LBLTF has a market cap of 4.1M. Regarding current trading prices, PBIO is priced at $0.00, while LBLTF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas LBLTF's P/E ratio is -0.01. In terms of profitability, PBIO's ROE is +0.70%, compared to LBLTF's ROE of +0.00%. Regarding short-term risk, PBIO is less volatile compared to LBLTF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check LBLTF's competition here
PBIO vs NUMD Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, NUMD has a market cap of 4M. Regarding current trading prices, PBIO is priced at $0.00, while NUMD trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas NUMD's P/E ratio is 4.76. In terms of profitability, PBIO's ROE is +0.70%, compared to NUMD's ROE of +0.35%. Regarding short-term risk, PBIO and NUMD have similar daily volatility (0.00).Check NUMD's competition here
PBIO vs ADMT Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ADMT has a market cap of 3.9M. Regarding current trading prices, PBIO is priced at $0.00, while ADMT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ADMT's P/E ratio is -5.79. In terms of profitability, PBIO's ROE is +0.70%, compared to ADMT's ROE of -0.63%. Regarding short-term risk, PBIO and ADMT have similar daily volatility (0.00).Check ADMT's competition here
PBIO vs VANIW Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, PBIO is priced at $0.00, while VANIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas VANIW's P/E ratio is N/A. In terms of profitability, PBIO's ROE is +0.70%, compared to VANIW's ROE of -1.33%. Regarding short-term risk, PBIO is less volatile compared to VANIW. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check VANIW's competition here
PBIO vs TBRIF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, TBRIF has a market cap of 3.3M. Regarding current trading prices, PBIO is priced at $0.00, while TBRIF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas TBRIF's P/E ratio is -0.88. In terms of profitability, PBIO's ROE is +0.70%, compared to TBRIF's ROE of -2.28%. Regarding short-term risk, PBIO is less volatile compared to TBRIF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check TBRIF's competition here
PBIO vs PMEDF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, PMEDF has a market cap of 2.8M. Regarding current trading prices, PBIO is priced at $0.00, while PMEDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas PMEDF's P/E ratio is -1.46. In terms of profitability, PBIO's ROE is +0.70%, compared to PMEDF's ROE of +1.68%. Regarding short-term risk, PBIO and PMEDF have similar daily volatility (0.00).Check PMEDF's competition here
PBIO vs ESMC Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ESMC has a market cap of 2.4M. Regarding current trading prices, PBIO is priced at $0.00, while ESMC trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ESMC's P/E ratio is 6.40. In terms of profitability, PBIO's ROE is +0.70%, compared to ESMC's ROE of +0.00%. Regarding short-term risk, PBIO is less volatile compared to ESMC. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check ESMC's competition here
PBIO vs ODYY Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, ODYY has a market cap of 2.2M. Regarding current trading prices, PBIO is priced at $0.00, while ODYY trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas ODYY's P/E ratio is -0.15. In terms of profitability, PBIO's ROE is +0.70%, compared to ODYY's ROE of +2.30%. Regarding short-term risk, PBIO is less volatile compared to ODYY. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check ODYY's competition here
PBIO vs UAHC Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, UAHC has a market cap of 2.1M. Regarding current trading prices, PBIO is priced at $0.00, while UAHC trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas UAHC's P/E ratio is 0.98. In terms of profitability, PBIO's ROE is +0.70%, compared to UAHC's ROE of +0.07%. Regarding short-term risk, PBIO and UAHC have similar daily volatility (0.00).Check UAHC's competition here
PBIO vs BIEL Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, BIEL has a market cap of 1.8M. Regarding current trading prices, PBIO is priced at $0.00, while BIEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas BIEL's P/E ratio is N/A. In terms of profitability, PBIO's ROE is +0.70%, compared to BIEL's ROE of +0.04%. Regarding short-term risk, PBIO is less volatile compared to BIEL. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check BIEL's competition here
PBIO vs USAQ Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, USAQ has a market cap of 1.7M. Regarding current trading prices, PBIO is priced at $0.00, while USAQ trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas USAQ's P/E ratio is -3.85. In terms of profitability, PBIO's ROE is +0.70%, compared to USAQ's ROE of +0.67%. Regarding short-term risk, PBIO and USAQ have similar daily volatility (0.00).Check USAQ's competition here
PBIO vs CRRVF Comparison July 2025
PBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PBIO stands at 4.1K. In comparison, CRRVF has a market cap of 1.5M. Regarding current trading prices, PBIO is priced at $0.00, while CRRVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PBIO currently has a P/E ratio of N/A, whereas CRRVF's P/E ratio is N/A. In terms of profitability, PBIO's ROE is +0.70%, compared to CRRVF's ROE of +0.00%. Regarding short-term risk, PBIO is less volatile compared to CRRVF. This indicates potentially lower risk in terms of short-term price fluctuations for PBIO.Check CRRVF's competition here